ATE421889T1 - Decoy-enthaltende pharmazeutische zusammensetzungen zur behandlung von aneurysmen - Google Patents
Decoy-enthaltende pharmazeutische zusammensetzungen zur behandlung von aneurysmenInfo
- Publication number
- ATE421889T1 ATE421889T1 AT02711288T AT02711288T ATE421889T1 AT E421889 T1 ATE421889 T1 AT E421889T1 AT 02711288 T AT02711288 T AT 02711288T AT 02711288 T AT02711288 T AT 02711288T AT E421889 T1 ATE421889 T1 AT E421889T1
- Authority
- AT
- Austria
- Prior art keywords
- decoy
- ets
- pharmaceutical compositions
- containing pharmaceutical
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Virology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2002/000865 WO2003063911A1 (fr) | 2002-02-01 | 2002-02-01 | Compositions pharmaceutiques contenant un leurre et procede d'utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE421889T1 true ATE421889T1 (de) | 2009-02-15 |
Family
ID=27639283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02711288T ATE421889T1 (de) | 2002-02-01 | 2002-02-01 | Decoy-enthaltende pharmazeutische zusammensetzungen zur behandlung von aneurysmen |
Country Status (6)
Country | Link |
---|---|
US (5) | US20040072726A1 (de) |
EP (1) | EP1470826B1 (de) |
JP (1) | JPWO2003063911A1 (de) |
AT (1) | ATE421889T1 (de) |
DE (1) | DE60231063D1 (de) |
WO (1) | WO2003063911A1 (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT732929E (pt) * | 1993-10-29 | 2008-08-26 | Brigham & Womens Hospital | Utilização terapêutica de ''engodos'' de elementos cis in vivo |
TWI308492B (de) * | 2001-02-20 | 2009-04-11 | Anges Mg Inc | |
US7378509B2 (en) * | 2003-12-02 | 2008-05-27 | Anesiva, Inc. | NF-kappaB oligonucleotide decoy molecules |
US7482158B2 (en) | 2004-07-01 | 2009-01-27 | Mathison Brian H | Composite polynucleic acid therapeutics |
EP1799271A4 (de) * | 2004-09-21 | 2010-05-05 | Anesiva Inc | Abgabe von polynucleotiden |
EP1803811B1 (de) * | 2004-10-22 | 2011-05-11 | AnGes MG, Inc. | Chimäre (doppel-) attrappe |
US7585848B2 (en) * | 2005-01-11 | 2009-09-08 | Rush University Medical Center | Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc |
EP1892293A4 (de) * | 2005-06-06 | 2008-12-10 | Anges Mg Inc | Transkriptionsfaktorköder |
CA2634291A1 (en) * | 2005-12-22 | 2007-06-28 | Institut De Cardiologie De Montreal | Transcription factor decoy oligodeoxynucleotides having multiple cis elements |
US20100105762A1 (en) * | 2007-02-16 | 2010-04-29 | Ryuichi Morishita | Therapeutic agent for periodontal disease and alveolar bone loss due to surgery |
NZ599881A (en) * | 2009-12-03 | 2014-01-31 | Novartis Ag | Hydrophilic filtration during manufacture of vaccine adjuvants |
ES2753274T5 (es) * | 2015-08-21 | 2023-05-26 | 42 Life Sciences Gmbh & Co Kg | Composición y procedimiento de hibridación |
WO2018067165A1 (en) * | 2016-10-07 | 2018-04-12 | Miami University | Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer |
CN114304053A (zh) * | 2021-12-10 | 2022-04-12 | 广东金石医疗科技服务有限公司 | 一种兔动脉瘤模型的构建方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5575815A (en) * | 1988-08-24 | 1996-11-19 | Endoluminal Therapeutics, Inc. | Local polymeric gel therapy |
US5225212A (en) * | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US5994314A (en) * | 1993-04-07 | 1999-11-30 | Inhale Therapeutic Systems, Inc. | Compositions and methods for nucleic acid delivery to the lung |
PT732929E (pt) * | 1993-10-29 | 2008-08-26 | Brigham & Womens Hospital | Utilização terapêutica de ''engodos'' de elementos cis in vivo |
PT824918E (pt) * | 1995-05-12 | 2007-06-22 | Anges Mg Inc | Tratamento e prevenção para doenças causadas pelo nf-kb |
US7034007B1 (en) * | 1995-06-07 | 2006-04-25 | East Carolina University | Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion |
US6271206B1 (en) * | 1996-09-12 | 2001-08-07 | Valentis, Inc. | Sonic nebulized nucleic acid/cationic liposome complexes and methods for pulmonary gene delivery |
JP4215219B2 (ja) * | 1997-07-04 | 2009-01-28 | アンジェスMg株式会社 | 脳保護剤 |
CN100532559C (zh) | 2000-02-02 | 2009-08-26 | 安增子摩祺株式会社 | 用于基因转移的病毒包膜载体 |
US6936468B2 (en) | 2000-04-28 | 2005-08-30 | University Of Pittsburgh | Use of tolerogenic dendritic cells for enhancing tolerogenicity in a host and methods for making the same |
JP4346233B2 (ja) | 2000-12-27 | 2009-10-21 | アンジェスMg株式会社 | デコイを含む薬学的組成物およびその使用方法 |
EP1355907A1 (de) * | 2001-01-31 | 2003-10-29 | Pfizer Products Inc. | "thiazolyl-, oxazolyl-, pyrrolyl- und imidazolyl-säureamidderivate, die sich als inhibitoren von pde4-isozymen eignen" |
-
2002
- 2002-02-01 EP EP02711288A patent/EP1470826B1/de not_active Expired - Lifetime
- 2002-02-01 US US10/466,239 patent/US20040072726A1/en not_active Abandoned
- 2002-02-01 WO PCT/JP2002/000865 patent/WO2003063911A1/ja active Search and Examination
- 2002-02-01 DE DE60231063T patent/DE60231063D1/de not_active Expired - Lifetime
- 2002-02-01 JP JP2003563600A patent/JPWO2003063911A1/ja active Pending
- 2002-02-01 AT AT02711288T patent/ATE421889T1/de not_active IP Right Cessation
-
2003
- 2003-07-10 US US10/618,362 patent/US20040109843A1/en not_active Abandoned
-
2006
- 2006-05-26 US US11/442,585 patent/US20060263422A1/en not_active Abandoned
- 2006-10-12 US US11/580,748 patent/US7524830B2/en not_active Expired - Lifetime
-
2009
- 2009-01-07 US US12/349,824 patent/US8067388B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20070142314A1 (en) | 2007-06-21 |
WO2003063911A1 (fr) | 2003-08-07 |
US7524830B2 (en) | 2009-04-28 |
US8067388B2 (en) | 2011-11-29 |
US20100331395A1 (en) | 2010-12-30 |
US20060263422A1 (en) | 2006-11-23 |
US20040072726A1 (en) | 2004-04-15 |
EP1470826B1 (de) | 2009-01-28 |
DE60231063D1 (de) | 2009-03-19 |
EP1470826A1 (de) | 2004-10-27 |
EP1470826A4 (de) | 2005-05-25 |
JPWO2003063911A1 (ja) | 2006-01-19 |
US20040109843A1 (en) | 2004-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE421889T1 (de) | Decoy-enthaltende pharmazeutische zusammensetzungen zur behandlung von aneurysmen | |
ITRM20020596A0 (it) | Protesi vascolare ad impianto con tecnica combinata, laparoscopica edendovascolare, per la cura degli aneurismi dell'aorta addominale, e co | |
TNSN08079A1 (en) | Pharmaceutical compositions for the treatment of inner ear disorders | |
PT1183015E (pt) | Pastilha em multicamadas para administracao de uma combinacao fixa de tramadol e diclofenac | |
DE602004012816D1 (de) | Selbstexpandierbarer Stent und Stenteinbringungssystem zur Behandlung von Gefässerkrankungen | |
ATE448812T1 (de) | Beschichtung von stents mit verzögerter wirkstofffreisetzung | |
HUP0402594A2 (hu) | Rapamycint és származékait tartalmazó hatóanyag-leadó rendszerek érbetegségek megelőzésére és kezelésére | |
CY1112184T1 (el) | Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii | |
DK0801564T3 (da) | Anvendelse af nebivolol som et antiatherogent middel | |
CY1112932T1 (el) | Αναστολεις sμαd7 για τη θεραπευτικη αγωγη ασθενειων του κνς | |
UA86344C2 (ru) | Способ лечения сосудистых заболеваний | |
ATE256671T1 (de) | 2-phenyl-substituierte 1-(n-phenylaminoalkyl)- piperazin-derivate | |
WO2006047378A3 (en) | Biocompatible and hemocompatible amphiphilic coatings for drug deliver | |
DE602004008304D1 (de) | Pteridin-derivate zur behandlung von erkrankungen im zusammenhang mit tnf-alpha | |
NO994165L (no) | Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet | |
DK1220852T3 (da) | Substituerede diazepaner | |
PT1000046E (pt) | Derivados de piperazina activos no trato urinario inferior | |
IL170519A (en) | Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them | |
DE69630974D1 (de) | Hyaluronsäurerezeptoren bindende stoffe und deren verwendung zur behandlung von tumoren und restenose | |
WO2002083074A3 (en) | Methods for the treatment of hepatic disorders | |
ATE341323T1 (de) | Verwendung von darifenacin zur behandlung des harndrangs | |
CY1105308T1 (el) | Θepαπεια για υπep-ουρικαιμια | |
PT1183046E (pt) | Derivado de aminotetralina para a terapia de doencas cardiovasculares | |
AP2004003113A0 (en) | Use of an inhibitor or antagonist against tissue factor | |
NO20050933L (no) | Pravastatin farmasoytiske formuleringer og fremgangsmater for anvendelse derav |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |